SP
Subarno Paul
KIIT University, Kalinga Institute of Industrial Technology, University of Kalyani
About
Ph.D. Scholar
Cancer Biology Division
School of Biotechnology
KIIT deemed to be University
Employment
-
KIIT University DBT Project assistant2019 - 2021
Education
-
KIIT University PhD2021 - Present
-
Kalinga Institute of Industrial Technology M.Sc. Biotechnology2017 - 2019
-
University of Kalyani B.Sc. Molecular Biology and Biotechnology2014 - 2017
Projects & Funding
Projects & funding information is unavailable.
Publications (21)
- Talazoparib enhances the anti-angiogenic potential of quinacrine through the deregulation of P300 and GCN5 chromatin remodelers in patient-derived oral cancer stem cells Save
- Design, synthesis and biological evaluation of 2-phenylquinoxaline carbonyl piperazine derivatives as novel FASN inhibitors with anticancer activity Save
- Resveratrol nanoparticles inhibit epithelial-to-mesenchymal transition in oral cancer via p53-independent p21-mediated downregulation of survivin Save
- Combination of Resveratrol and PARP inhibitor Olaparib efficiently deregulates homologous recombination repair pathway in breast cancer cells through inhibition of TIP60-mediated chromatin relaxation Save
- Molecular editing of NSC-666719 enabling discovery of benzodithiazinedioxide-guanidines as anticancer agents Save
- Nano formulated Resveratrol inhibits PD-L1 in oral cancer cells by deregulating the association between tumor associated macrophages and cancer associated fibroblasts through IL-6/JAK2/STAT3 signaling axis Save
- Near infrared-responsive quinacrine–gold hybrid nanoparticles deregulate HSP-70/P300-mediated H3K14 acetylation in ER/PR+ breast cancer stem cells Save
- Scaffold overlay of flavonoid-inspired molecules: Discovery of 2,3-diaryl-pyridopyrimidin-4-imine/ones as dual hTopo-II and tubulin targeting anticancer agents Save
- Near-infrared enhances antiangiogenic potentiality of quinacrine-gold hybrid nanoparticles in breast cancer stem cells via deregulation of HSP-70/TGF-β Save
- Talazoparib enhances the Quinacrine-mediated apoptosis in patient-derived oral mucosa CSCs by inhibiting BER pathway through the modulation of GCN5 and P300 Save